Bactiguard Holding AB (publ) (BACTI_B) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bactiguard Holding Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.501 Thank you, Operator, and welcome to the presentation of Back to Guard's Q1 2025 00:00:05.501 -- 00:00:10.349 report. Our CFO, Patrick Bach, and I will go through the presentation together, and as 00:00:10.349 -- 00:00:15.475 usual, we will have a Q&A session towards the end. 00:00:16.400 -- 00:00:20.387 I will begin by sharing some brief comments on the first quarter results, and Patrick 00:00:20.387 -- 00:00:24.567 will go through the financials in more detail later in the presentation. 00:00:24.567 -- 00:00:29.755 Firstly, we are very pleased to again report both continued profitability and revenue 00:00:29.755 -- 00:00:34.764 growth. We delivered an EBITDA of 9.4 million SEC 00:00:34.764 -- 00:00:40.092 and revenues of 62.7 million SEC, which is an increase of almost 7% 00:00:40.092 -- 00:00:43.298 compared to Q1 last year. 00:00:43.298 -- 00:00:47.965 Increased license revenues stem primarily from our strengthened collaboration with med 00:00:47.965 -- 00:00:53.299 tech company BD. a prime example of a mutually beneficial relationship 00:00:53.299 -- 00:00:58.407 that is driving growth for both parties. I will provide a bit more detailed update 00:00:58.407 -- 00:01:01.532 regarding the BD partnership shortly. 00:01:01.532 -- 00:01:06.399 Another highlight for Q1 comes from our wound management portfolio. 00:01:06.399 -- 00:01:11.427 Revenues increased by more than 50% driven by sales of our Hydrosyn Aqua line 00:01:11.427 -- 00:01:13.269 of products. 00:01:13.269 -- 00:01:18.834 We now have four quarters in a row with positive financial development demonstrating 00:01:18.834 -- 00:01:23.238 that we are consistently doing what we said we would do and delivering on our promise 00:01:23.238 -- 00:01:28.623 of profitability follow...